Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal drink may soothe radiation mouth pain in cancer patients

NCT ID NCT07311772

Symptom relief Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether Houyanqing Oral Liquid, a Chinese herbal mix, can prevent or reduce severe mouth sores caused by radiation therapy in 386 nasopharyngeal cancer patients. Participants take the liquid four times daily during radiation, alongside standard care. The study aims to see if fewer patients develop grade 2 or worse mouth sores, and if their quality of life improves.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Houyanqing Oral Liquid (a Chinese herbal preparation)
What this could lead to
If it works, this could offer a new option to reduce painful mouth sores during radiation, improving quality of life for nasopharyngeal cancer patients.
What could go wrong
This is a single phase 3 trial with a herbal product, so results may not be widely applicable. The herbal mixture may cause side effects or interact with other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 386 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Staged as Stage I-IV according to the 9th edition of the TNM Classification of Malignant Tumors formulated by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC); 2. Age: 18 to 75 years old; 3. Karnofsky Performance Status (KPS) score ≥ 80 before treatment; 4. No oral diseases (such as oral mucositis or salivary gland damage) before radiotherapy; 5. Requiring radical radiotherapy; 6. The patient has signed the informed consent form and is willing and able to comply with the study's follow-up visits, treatment plan, laboratory tests, and other research procedures. Exclusion Criteria: 1. Patients with confirmed tumor recurrence, distant tumor metastasis, or who have received other anti-tumor treatments; 2. Previous history of head and neck radiotherapy; 3. Known allergy to the drugs used in this study (Houyanqing Oral Liquid, any conventional treatment drugs); 4. Local use of Houyanqing Oral Liquid, Recombinant Human Epidermal Growth Factor (rhEGF) Topical Solution, Vitamin B12 Solution, or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) mouthwash in the oral cavity within one month before enrollment; 5. Comorbidities requiring long-term treatment with immunosuppressive drugs, or systemic/local use of corticosteroids at immunosuppressive doses before enrollment; 6. HIV-positive patients; 7. Pregnant women or lactating women; 8. Patients with severe mental illnesses; 9. Patients with severe cardio-cerebrovascular diseases, endocrine disorders, infectious diseases, or other tumors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nasopharyngeal cancinoma (NPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced oral mucositis nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nasopharyngeal cancinoma (NPC) Radiation-induced oral mucositis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    16 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    RECRUITING

    Guangzhou, Guangdong, 510095, China

  • Cancer Hospital Chinese Academy of Medical Science

    RECRUITING

    Beijing, Beijing Municipality, 100021, China

  • Cancer Hospital of Guangxi Medical University

    RECRUITING

    Nanning, Guangxi, 530021, China

  • Cancer Hospital of Shantou University Medical College

    RECRUITING

    Shantou, Guangdong, 515041, China

  • Eye & ENT Hospital of Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200031, China

  • Fifth Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Zhuhai, Guangdong, 519000, China

  • Fujian Medical University Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350014, China

  • Hunan Cancer Hospital

    RECRUITING

    Changsha, Hunan, 410013, China

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

  • The First Affiliated Hospital of Kunming Medical University

    RECRUITING

    Kunming, Yunnan, 650032, China

  • The First People's Hospital of Changzhou

    RECRUITING

    Changzhou, Jiangsu, 213003, China

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, 610041, China

  • Wuzhou Red Cross Hospital

    RECRUITING

    Wuzhou, Guangxi, 543002, China

  • Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, 410008, China

  • Yunnan Cancer Hospital

    RECRUITING

    Kunming, Yunnan, 650118, China

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhengjiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.